

Immedica Pharma UK: Methodology for Disclosure of Transfers of Value (ToV) to Patients and the Public 2025

1. Introduction

This methodological note outlines how Immedica Pharma UK prepares its annual public disclosure of Transfers of Value (ToV) provided to members of the public, including patients and journalists, for activities conducted during the 2025 reporting year. It is prepared in accordance with the ABPI Code of Practice and follows the processes used for disclosure of 2025 activities.

The purpose of this methodology is to ensure clarity, transparency and consistency in how ToVs involving the public are defined, recorded, and disclosed.

2. Reporting Period

The reporting period covers a full calendar year (1 January – 31 December 2025).

3. Timing of Disclosure

In line with ABPI/IPHA requirements, Immedica will publish ToV disclosures within six months after the end of the reporting period.

All disclosed information will remain publicly available for a minimum of three years from first publication.

4. Accounting Basis

Immedica records Transfers of Value using the cash-basis principle. A ToV is therefore registered when payment is made, rather than when the activity itself occurred.

5. Definition of Transfers of Value (ToV)

For the purposes of this methodology, a ToV refers to:

- Financial support provided by Immedica, including monetary payments made directly to individuals.
- Significant indirect or non-financial support, such as services, resources, or in-kind contributions.
- Contracted services, where the total amount paid per patient over the reporting period is disclosed.

Each ToV must be accompanied by a clear, sufficiently complete description of the nature of the arrangement to allow the public to understand the interaction, without disclosing confidential information.

6. Scope of Disclosure

Disclosures relate to ToVs involving:

- Members of the public, including individual patients who provide contracted services or receive financial or non-financial support.
- Journalists, where relevant services or support fall within disclosure requirements.

This sits alongside (but separate from) the disclosure methodologies for:

- Healthcare Professionals and Organisations (HCP/HCO)
- Patient Organisations (POs)

The patient/public methodology mirrors broader Immedica UK disclosure principles to ensure consistency across all ToV categories.

7. Types of ToV Included

The following ToV types are included:

7.1 Financial Support

Monetary payments to individuals for:

- Participation in advisory or consultancy activities
- Speaking, attendance, or panel contributions
- Support for participation in research-related activities (where not classified as R&D in ABPI terms)

7.2 Non-Financial or Indirect Support

Examples include:

- Travel or accommodation (if applicable)
- Educational resources
- Services or materials with measurable value

7.3 Contracted Services

Immedica will disclose the total annual amount paid per patient for contracted services or activities undertaken during 2025.

7.4 Exclusions

Where ToVs fall into categories explicitly excluded in the broader disclosure methodology (e.g., certain R\&D, market research where anonymity is maintained), these will follow the rules set out in the general methodology.

8. Description Standards

Each disclosed ToV must include:

- A concise explanation of the nature of the service or support
- A description that is sufficiently complete for transparency
- No release of confidential or personally identifying medical information
-

9. Data Handling and Quality Controls

Immedica applies consistent corporate standards for:

- Data accuracy
- Quality checks
- Verification of ToV category and payment records

The patient/public disclosures adhere to the same overarching governance as the HCP/HCO and PO methodologies to ensure accuracy and compliance.

10. Publication

All interactions with patient organisations are already published on the Immedica global website, and ToVs involving individual patients or the public will follow the same transparent approach.

The disclosure will be accessible in a publicly available format on Immedica's website for the required duration.

11. Data Protection

Personal data will be processed in accordance with Immedica's standard privacy notices and applicable UK data protection laws (e.g., UK GDPR), ensuring:

- Minimum necessary personal data is disclosed
- Individuals are informed of required transparency obligations

12. Contact for Queries

Any questions regarding this methodology or the disclosure dataset can be directed to Immedica Pharma UK's Transparency or Medical Affairs team.